Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
https://investor.todosmedical.com/news-events/press-releases/detail/107/todos-medical-enters-into-automation-and-reagent-supply
NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has entered into an automation and reagent supply agreement with MAJL Diagnostics (“MAJL”). Under the terms of the agreement, Todos will implement its automation solution, including Tecan™ liquid handlers, automated RNA extraction machines, as well as a 384-well PCR machine capable of conducting COVID, cancer genetics and pharmacogenomics testing, in order to become the provider of all COVID-19 PCR testing reagents and supplies. Upon completion of the automation process, MAJL will be capable of processing approximately 1,500 PCR COVID-19 tests per day.
“We are very excited to work with MAJL as they look to increase their capacity for COVID-19 testing and we continue to expand the geographic footprint of our install-base,” said Gerald E. Commissiong, President & CEO of Todos. “Our automation solution will enable MAJL to scale their testing capacity significantly and give them the ability to actively engage with larger business opportunities, including school districts in the Atlanta area. As MAJL increases its testing capacity, we look forward to helping with their growth, providing additional automation as needed.”
“We were very impressed with the system Todos has been able to put together,” said Lisa Cloud, President & CEO of MAJL Diagnostics. “We look forward to growing our COVID-19 PCR testing business in the months ahead and believe Todos’ scalable solution provides us with the flexibility to expand our capabilities proportionately with our marketing efforts.”
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com
For testing and PPE inquiries, please email sales@todosmedical.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF), engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed a strategic partnership with Integrated Health LLC to deploy mobile COVID-19 testing in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target the reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Investor Contact:
Richard Galterio
Ascendant Partners LLC
Managing Partner
732-642-7770
rich@ascendantpartnersllc.com
Todos Corporate Contact:
Priyanka Misra
Todos Medical
(917) 983-4229 ext. 103
priyanka@todosmedical.com
Outstanding Shares Update - 3/19/21
https://www.otcmarkets.com/stock/tomdf/security
How do we know this? Is that an assumption or you have proof? We know GC reads Twitter but is there any evidence he reads this board?
Has GC's attorneys contacted someone who posts here? JP perhaps?
What names got GC use? Please enlighten us.
What statement is unfair? My response that freedom of speech doesn't mean you can say anything you want whenever you want? My response was to correct that misconception.
If someone here posts that another poster is an idiot for trusting Gerald, that post can be deleted for violating TOU. You have the right to post your opinion, but the site sets the rules here, and freedom of speech is not protected here. Your post will get deleted. That's all I'm saying.
I do understand your view and I'm not trying to change it. However, the growth in Todos revenues didn't happen as a fluke. Someone drove that, and I suspect it was GC. Whether that results in a successful investment remains to be seen, but at least give the man credit where credit is due. No revenue was even generated at Amarantus, to my knowledge. Perhaps this time things will be different. Perhaps not.
Freedom of speech is only protected under the U.S. Constitution from government suppression. We are not free to say or post anything we want, especially when rights of others are infringed upon. This board has TOU requirements and posting something that violates those will get the message removed. IHub sets the rules for their forum.
Also, going in to a private business and publicly calling the owner a crook to warn other customers will likely get the person tossed out on their head and a slander lawsuit filed against them, which they would lose if they cannot prove their accusations in court.
So, while one can say whatever they want wherever they want, they're not always under the protection of freedom of speech and adverse consequences may result. Someone feeling the need to protest by burning an American flag in the front yard of a veteran probably wouldn't end well for that individual. You are free to post your opinions of GC here as long as you don't violate TOU. We all understand the fascination you have with him and need to grind the axe.
Since we're grinding the axe here, remind us how much GC suckered you to invest in the AMBS? Did dreams of riches cloud good judgement by betting so much in a high risk penny stock? Was it all the CEO's fault? Any personal responsibility at all for the decision? No considering the possibility things might not work out as predicted?
Then, by all means... say no more.
no more needs to be said
Outstanding Shares Update
https://www.otcmarkets.com/stock/tomdf/security
I'm not defending the CEO. I have some of the same concerns as some here, but I haven't invested so much that I'm pissing my pants or losing sleep at night because things aren't progressing as fast as some wish. I have not voted.. But if anyone here cannot accept others having a different opinion than their own, they have a problem they need to address with themselves.
GC has been CEO since 1/9/20, only a bit over a year ago, and in that time he pivoted the company's focus based on the emerging COVID-19 pandemic. In that time he has led the company from essentially zero revenue to millions per month. Yet because some here have an axe to grind from past investments in other companies involving GC, they are on a mission to encourage everyone to vote to request he be fired as CEO. Some of those pushing it have no investment in Todos and never have. If you feel he should go, then by all means vote your conscious, but at least see their motives for what they are. They're likely less concerned about us as Todos investors and more focused on grinding their axe.
The company internal operations are not fully known to use as investors. We only know what is published in filings and what we can glean from press releases and Twitter responses. In regards to your question as to why GC would continue with convertible debt when we have reached positive cash flow, I observe that both occurred close to the same time so in my mind the last round of convertible funding is likely for moving forward with initiatives that need to go forward now instead of waiting for enough free cash flow to cover them. That's just an educated guess based on all available information.
Many here complain about the dilution. That seems to be a common practice among underfunded penny stocks trying to reach success. If one doesn't like it, don't invest in this space, at least not more than you can afford to lose. I have never operated a public penny stock company and I doubt anyone here has either, yet so many armchair quarterbacks feel they could easily do better. Maybe so, but then perhaps they should put together some viable options from interested investors and present them to the company CFO and CEO. Maybe it would make a difference. Probably not.
I find it comical that some posters who are constantly ragging on GC regarding dilution are invested in companies such as WOGI that has 2.95 billion shares issued and seem to have no issue there. That is part of my "axe to grind" reasoning.
Typo on earlier post: AMONG should be AMOUNT
I'm not disagreeing with you on the social media angle, which I suppose this board is a part of. I'm pointing out that some who only post here and nowhere else should not assume GC reads this board. Their concerns should be brought to other platforms such as Twitter where there is proof he reads and responds frequently.
I have my own exit strategy here, and it may be adjusted depending on how things with Todos unfold. But thanks for offering your input.
I get it. Personal axe to grind with no investment in Todos shares.
Perhaps we can also start a petition to have the Governor of California or President of Mexico removed. Not being a citizen of either of those areas makes no difference. First Amendment right to express one's opinion and all. I get it.
As a holder of a sizable number of Todos shares, I am keeping my focus on the longer game, not on the lack of frequent updates from the company in order to provide shareholder handholding and keep me from pissing my pants because I might have too much invested in a high-risk penny stock. I'm sure some here do have too much invested and are hoping to strike it rich, but also fretting because they have far too much invested than they can afford to lose. All I can say to that is...I wish them luck. And I hope they won't blame the CEO for their losses when THEY decided to invest more than they could afford to lose in a high-risk investment. Doesn't matter what the CEO states or promises to do. One has to look at the risk profile of the type of investment. While one can put some of the blame on the CEO for the decision to invest here if the CEO lies or mismanages, the ownership of the AMOUNG invested rests squarely on the shoulders of the investor, not the CEO, in my opinion. Greed of the individual is not the fault of the CEO.
I understand some here lost money in AMBS. It's clear to me the story isn't the same because Todos is actually generating millions per month in revenues. I understand having a different opinion, but again it's coming from someone with no money at stake here, so why would I care? Clearly, axe to grind.
Some are posting their concerns, but when those posts attack another poster they are in violation of TOS and are removed so you may not have seen them.
Plenty of investors contacting GC on Twitter to speak up. GC probably doesn't read this board, so posting concerns here should only for other investors to discuss. GC needs to hear investors concerns directly via Twitter, emails or phone calls. At least he then hears the concerns, although he may not reply.
Outstanding Shares Update
https://www.otcmarkets.com/stock/tomdf/security
https://video.foxbusiness.com/v/6231268077001#sp=show-clips
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
https://aditxt.com/investor-relations/press-releases/
https://video.foxbusiness.com/v/6231268077001#sp=show-clips
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
https://aditxt.com/investor-relations/press-releases/
Let me think about it...
(5 seconds later)
Okay, i've thought about it. Business and revenues are growing. Yozma has done their DD and taken a stake in Todos. I have no axe to grind.
CONCLUSION: I will BUY more shares of Todos.
Most every successful person has a story of excruciating failure in their past — and for good reason – Business Insider
https://www.businessinsider.com/success-failure-ceo-jean-case-2019-1
Great read and relevant here since Amarantus has a stake in Todos Medical. Multiple revenue-generating contracts and revenues growing substantially month-to-month at Todos. CEO performing better than in the past.
Most every successful person has a story of excruciating failure in their past — and for good reason – Business Insider
https://www.businessinsider.com/success-failure-ceo-jean-case-2019-1
Great read and relevant here. Clearly there are differences in CEO performance at the last company and this company. Multiple revenue-generating contracts here. Never had that in the prior company.
Don't like the CEO? Don't think the CEO can learn from past mistakes? Don't invest.
Investors on this board are aware of the CEO's past with AMBS and don't need someone who has no investment in Todos grinding their personal axe here. Please post your grievances on the AMBS board where they belong. After all, that's where your investment losses occurred.
Thanks for trying to save us. Now go back to the AMBS board and let us make our own investment decisions here. We promise not to cry and blame the CEO if we lose our money. Enough of that going on already.